Therapeutic heparin for preventing COVID-19 deaths is four times higher than the prophylactic dose

By | October 30, 2021
The anti-coagulant heparin reduces the likelihood of death from COVID-19 by 78% when administered in therapeutic doses to patients with signs of respiratory failure on admission to hospital, according to a study reported on October 14 in the British Medical Journal.